复方牛胎肝提取物治疗慢性乙型肝炎疗效观察

Efficacy of co mpound embryonic bovine liver extract tablets in treatment of patients with chronic hepatitis B

目的观察复方牛胎肝提取物片治疗慢性乙型肝炎患者的疗效。方法 120例慢性乙型肝炎患者被随机分为治疗组64例和对照组56例。对照组给予基础治疗,治疗组加用复方牛胎肝提取物治疗3 m,观察两组治疗前后临床、肝功能和肝纤维化指标的变化。结果在3 m治疗结束时,治疗组乏力和纳差的改善率分别为92.00%和91.84%,显著高于对照组(56.41%和58.33%,P<0.05);治疗组ALT为(35.6±17.2)U/L、AST为(38.5±18.6)U/L、GGT为(40.6±19.7)U/L、总胆红素为(16.1±13.9)μmol/L,均较治疗前[分别为(110.8±61.4)U/L、(97.2±62.4)U/L、(106.3±60.1)U/L、(47.8±19.3)μmol/L)]显著下降(P<0.05);治疗组基线时III型前胶原肽为(36.7±11.3)μg/L、透明质酸为(276.4±79.5)μg/L、层粘连蛋白为(169.8±73.4)μg/L、IV型胶原为(155.8±61.5)μg/L,治疗后均显著下降[分别为(16.4±6.1)μg/L、(110.8±51.4)μg/L、(70.8±34.9)μg/L、(97.8±41.4)μg/L,P<0.05)]。结论复方牛胎肝提取物片治疗慢性乙型肝炎患者有一定的效果。

Objective To observe the efficacy of compound embryonic bovine liver extract tablets in treat-ment of patients with chronic hepatitis B（CHB）. Methods One hundred and twenty patients with CHB were re-cruited, and divided randomly into control group（n=56）or treatment group （n=64）;Patients in control group were treated with basic liver-protecting treatment and patients in treatment group were treated with combinational ther-apy of compound embryonic bovine liver extract tablets and basic treatment. Changes in liver function tests and fibrotic parameters were examed after 3 months of treatment. Results At the end of 3 months of treatment,the fatigue and poor appetite were improved in 92.00% and 91.84%,respectively,in treatment group,significantly high-er than those in controls （56.41% and 58.33%,respectively,P〈0.05）;the serum ALT, AST, GGT and total biliru-bin levels in treatment group were （35.6±17.2） U/L,（38.5±18.6） U/L,（40.6±19.7） U/L and （16.1±13.9） μmol/L, respectively,significantly decreased than those before treatment [（110.8±61.4） U/L for ALT,（97.2±62.4） U/L for AST,（106.3±60.1） U/L for GGT and （47.8±19.3） μmol/L for total bilirubin,P〈0.05];serum PIIIP （36.7±11.3 μg/L）, HA （276.4 ±79.5 μg/L）,LN（169.8 ±73.4 μg/L） and IV-C （155.8 ±61.5 μg/L） in treatment group decreased significantly than those before treatment [（16.4±6.1） μg/L for PIIIP,（110.8±51.4） μg/L for HA,（70.8±34.9） μg/L for LN and （97.8 ±41.4） μg/L for IV-C,P〈0.05],which lowered more obviously than in control. Conclusion Compound embryonic bovine liver extract may be a promising therapeutic remedy for patients with CHB.